优化重症监护病房新冠肺炎患者羟氯喹的给药方案
Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.
作者信息
Perinel Sophie, Launay Manon, Botelho-Nevers Élisabeth, Diconne Éric, Louf-Durier Aurore, Lachand Raphaël, Murgier Martin, Page Dominique, Vermesch Régine, Thierry Guillaume, Delavenne Xavier
机构信息
Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire (CHU) de Saint-Etienne, France.
Institut National de la Santé et de la Recherche Médicale U1059, Dysfonctions Vasculaires et de L'Hémostase, Université de Lyon, Saint-Etienne, France.
出版信息
Clin Infect Dis. 2020 Nov 19;71(16):2227-2229. doi: 10.1093/cid/ciaa394.
Abstract
Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.
摘要
羟氯喹啉（HCQ）似乎是一种有前景的治疗新型冠状病毒肺炎（COVID-19）的药物。然而，目前所有关于HCQ的正在进行的临床试验都采用了不同的给药方案，导致了不同的浓度。因此，需要进行药代动力学研究来确定最佳给药方案。
相似文献
1
Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.优化重症监护病房新冠肺炎患者羟氯喹的给药方案
Clin Infect Dis. 2020 Nov 19;71(16):2227-2229. doi: 10.1093/cid/ciaa394.
2
Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.模型指导下的 COVID-19 患者羟氯喹给药：近期经验教训、尚存不确定性和差距。
Br J Clin Pharmacol. 2021 Feb;87(2):674-682. doi: 10.1111/bcp.14436. Epub 2020 Jul 19.
3
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防（PROLIFIC）以预防一线医护人员感染 COVID-19：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
4
Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.开发一种用于 COVID-19 患者肺部给药的雾化羟氯喹的基于生理的药代动力学（PBPK）模型。
Drug Res (Stuttg). 2021 May;71(5):250-256. doi: 10.1055/a-1325-0248. Epub 2020 Dec 30.
5
Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.羟氯喹在 COVID-19 重症患者肺部的药代动力学。
Int J Antimicrob Agents. 2021 Feb;57(2):106247. doi: 10.1016/j.ijantimicag.2020.106247. Epub 2020 Nov 28.
6
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.羟氯喹在新冠肺炎患者中的群体药代动力学：对剂量优化的启示。
Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y.
7
Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations.基于新冠肺炎患者特征的羟氯喹给药方案优化：文献综述与模拟分析
Xenobiotica. 2021 Feb;51(2):127-138. doi: 10.1080/00498254.2020.1824301. Epub 2020 Sep 30.
8
Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.羟氯喹在 COVID-19 住院患者中的药代动力学和药效学。
Therapie. 2021 Jul-Aug;76(4):285-295. doi: 10.1016/j.therap.2021.01.056. Epub 2021 Jan 28.
9
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.模拟评估治疗儿童 COVID-19 的新型治疗方法的药代动力学指导剂量。
JAMA Pediatr. 2020 Oct 1;174(10):e202422. doi: 10.1001/jamapediatrics.2020.2422. Epub 2020 Oct 5.
10
A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.用靶向递送达比洛索芬的吸入性脂质体治疗 COVID-19 疾病的策略：一项临床前药代动力学研究。
Clin Transl Sci. 2021 Jan;14(1):132-136. doi: 10.1111/cts.12923. Epub 2020 Nov 30.
引用本文的文献
1
The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.新型肺部靶向心脏安全羟氯喹吸入性气凝胶的体外、体内和 PBPK 评价。
AAPS PharmSciTech. 2023 Aug 11;24(6):172. doi: 10.1208/s12249-023-02627-3.
2
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).新型冠状病毒病（COVID-19）的现有药物和预防性疫苗概述。
Cell Mol Biol Lett. 2022 May 13;27(1):38. doi: 10.1186/s11658-022-00339-3.
3
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.氯喹治疗糖尿病合并 COVID-19 患者的安全性考虑。
Chem Biol Interact. 2022 Jul 1;361:109954. doi: 10.1016/j.cbi.2022.109954. Epub 2022 Apr 22.
4
Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.羟氯喹及其3种代谢产物在新冠肺炎患者中的群体药代动力学及药代动力学/药效学应用
Pharmaceuticals (Basel). 2022 Feb 21;15(2):256. doi: 10.3390/ph15020256.
5
Mass spectrometry applied to diagnosis, prognosis, and therapeutic targets identification for the novel coronavirus SARS-CoV-2: A review.质谱分析在新型冠状病毒 SARS-CoV-2 的诊断、预后和治疗靶点鉴定中的应用：综述。
Anal Chim Acta. 2022 Feb 22;1195:339385. doi: 10.1016/j.aca.2021.339385. Epub 2021 Dec 20.
6
Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study.2019冠状病毒病（COVID-19）患者的羟氯喹血清浓度：一项回顾性研究。
Forensic Sci Res. 2021 Aug 19;6(3):215-217. doi: 10.1080/20961790.2021.1936896. eCollection 2021.
7
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.羟氯喹联合阿奇霉素早期治疗门诊轻中度 COVID-19：一项评估病毒清除率的随机、双盲、安慰剂对照临床试验。
Int J Antimicrob Agents. 2021 Nov;58(5):106428. doi: 10.1016/j.ijantimicag.2021.106428. Epub 2021 Aug 25.
8
Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients.基于模型的新冠病毒药物重新利用：儿科患者抗病毒活性推断及剂量依据
Pharmaceutics. 2021 Aug 19;13(8):1299. doi: 10.3390/pharmaceutics13081299.
9
Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.抗疟药物——它们对风湿和病毒性疾病有益吗？——在 COVID-19 大流行期间的考虑因素。
Clin Rheumatol. 2022 Jan;41(1):1-18. doi: 10.1007/s10067-021-05805-5. Epub 2021 Jul 3.
10
Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report.在系列鼻咽拭子检测呈阴性的情况下，通过支气管肺泡灌洗检测到的严重急性呼吸综合征冠状病毒2感染：一例报告
Ann Transl Med. 2021 Apr;9(7):583. doi: 10.21037/atm-20-4307.
Zotero 插件